Earnings summaries and quarterly performance for Lantern Pharma.
Executive leadership at Lantern Pharma.
Board of directors at Lantern Pharma.
Research analysts who have asked questions during Lantern Pharma earnings calls.
Recent press releases and 8-K filings for LTRN.
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
LTRN
New Projects/Investments
- Lantern Pharma's LP-284 has been granted FDA Orphan Drug Designation (ODD) for the treatment of soft tissue sarcomas. This marks the third ODD for LP-284 and the sixth overall for Lantern Pharma's clinical programs.
- The designation expands LP-284's potential to address an estimated ~96,000 global annual soft tissue sarcoma cases, with the market for therapeutics projected to grow from $2.4 billion in 2025 to $4.7 billion by 2035.
- Orphan Drug Designation provides strategic benefits, including seven years of market exclusivity upon regulatory approval, tax credits for qualified clinical trials, and exemption from FDA user fees.
Jan 20, 2026, 1:00 PM
Lantern Pharma Establishes AI Center of Excellence in India
LTRN
New Projects/Investments
Hiring
Revenue Acceleration/Inflection
- Lantern Pharma has established an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India, to industrialize its RADR® platform and expand its AI capabilities beyond oncology into new disease categories.
- The company anticipates that the expansion and hiring for initial positions will be cash flow neutral and expects immediate tangible results in Q1 2026.
- This strategic initiative aims to scale Lantern's AI platform globally, enhance computational capacity, and accelerate development cycles, positioning the company for systematic revenue generation through collaborations with biopharma partners.
- Lantern Pharma will host an Investor and Analyst Day on January 22, 2026, in New York City to provide further details on the AI Center of Excellence and announce a major platform rollout.
Jan 12, 2026, 2:00 PM
Lantern Pharma Reports Positive Phase 1a Results for LP-184
LTRN
New Projects/Investments
- Lantern Pharma's lead drug candidate, LP-184, successfully completed its Phase 1a dose-escalation study in heavily pre-treated patients with advanced solid tumors, meeting all primary safety and tolerability endpoints and establishing a recommended Phase 2 dose.
- The study demonstrated a 54% disease control rate among patients receiving therapeutic doses, particularly in tumors with DNA damage repair pathway deficiencies.
- The company is advancing multiple biomarker-guided Phase 1b/2 clinical trials for cancers including triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, and advanced urothelial carcinoma.
- These results validate Lantern's proprietary RADR® AI platform and its AI-driven drug development approach, with LP-184 having an estimated aggregate annual market opportunity exceeding $10 billion.
- LP-184 has received three FDA Orphan Drug designations, two FDA Fast Track designations, and a Rare Pediatric Disease designation.
Dec 3, 2025, 3:14 PM
Lantern Pharma Presents Positive LP-184 Clinical Trial Results
LTRN
New Projects/Investments
Product Launch
- Lantern Pharma has completed its Phase IA study for LP-184, an investigational drug for advanced solid tumors, demonstrating good safety and tolerability and encouraging clinical activity across various tumor types.
- The study highlighted durable stable disease in several patients, with some remaining on treatment for over 12 months, including a patient with thymic carcinoma showing a 26% lesion reduction and a non-small cell lung cancer patient with a 22% lesion reduction.
- LP-184 targets tumors with DNA damage repair deficiencies and high PTGR1 expression, with preclinical data suggesting 20-400 times higher potency than gemcitabine in pancreatic cancer models and the ability to overcome PARP inhibitor resistance.
- The company is planning Phase IB/II clinical trials for LP-184 in relapsed/metastatic triple-negative breast cancer, non-small cell lung cancer, and bladder cancer, including combination studies.
- LP-184 has received three orphan designations and two fast-track designations, indicating significant regulatory recognition and market potential.
Nov 20, 2025, 9:30 PM
Lantern Pharma Reports LP-184 Phase IA Clinical Trial Results
LTRN
Product Launch
New Projects/Investments
- Lantern Pharma's investigational drug, LP-184, designed for advanced solid tumors with DNA damage repair deficiencies, has completed its Phase IA clinical trial, demonstrating good safety and tolerability and encouraging clinical activity.
- Out of 28 heavily pretreated patients dosed, four achieved durable stable disease for over six months. A patient with squamous non-small cell lung cancer with a BRCA1 alteration has been on treatment for approximately two years (34 cycles), showing a 22% target lesion reduction.
- LP-184 has received three orphan designations and two fast-track designations, including one for triple-negative breast cancer.
- Planned Phase IB/II clinical trials include monotherapy for triple-negative breast cancer with homologous recombination deficiency, combination therapy for non-small cell lung cancer, and an investigator-sponsored trial for bladder cancer.
Nov 20, 2025, 9:30 PM
Lantern Pharma Announces Positive LP-184 Phase I-A Clinical Trial Results and Future Development Plans
LTRN
New Projects/Investments
- Lantern Pharma has completed its Phase I-A study for LP-184, demonstrating a favorable safety profile with mostly Grade 1 and 2 adverse events, and encouraging clinical activity in advanced solid tumors, particularly those with DNA damage repair deficiencies.
- LP-184 has been granted three orphan designations and two fast-track designations, with a market potential described as "blockbuster-like".
- Preclinical data indicates LP-184's potential to be superior to PARP inhibitors in certain contexts and to overcome resistance to existing therapies.
- Upcoming Phase I-B/II clinical trials are planned for triple-negative breast cancer, non-small cell lung cancer, and bladder cancer, with a recommended Phase II dose at dose level 10.
Nov 20, 2025, 9:30 PM
Lantern Pharma Reports Q3 2025 Results and Advances Clinical Pipeline and AI Platform
LTRN
Earnings
New Projects/Investments
Guidance Update
- Lantern Pharma reported a net loss of $4.2 million, or $0.39 per share, for Q3 2025, and held $12.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund operations into approximately Q3 2026. The company also sold 212,444 shares of common stock under an ATM agreement for $989,000 during Q3 2025.
- The company achieved significant clinical milestones, with its LP-184 Phase 1a clinical trial successfully meeting all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients. Preliminary Phase 2 data for LP-300 showed an 86% clinical benefit rate.
- Lantern Pharma is positioning LP-184 for four targeted Phase 1b/Phase 2 trials across indications with a combined annual market potential exceeding $7 billion, and its subsidiary Starlight Therapeutics received FDA Fast Track and Orphan drug designation for a pediatric CNS cancer trial.
- The company is commercializing its RADR AI platform, showcasing modules like PredictBBB (achieving 94% accuracy for blood-brain barrier permeability prediction) and LBX AI (achieving 86-90% accuracy in predicting treatment response), and introduced Zeta, a new multi-agentic AI platform for rare cancer research.
Nov 13, 2025, 2:00 PM
Lantern Pharma Reports Q3 2025 Results and Clinical Trial Progress
LTRN
Earnings
New Projects/Investments
Guidance Update
- Lantern Pharma reported a net loss of $(4,177,423) and a net loss per common share of $(0.39) for Q3 2025. The company held approximately $12.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025, projecting an operating runway into approximately Q3 2026.
- The LP-184 Phase 1a clinical trial achieved all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients and marked tumor reductions in patients with specific DNA damage repair mutations.
- The company demonstrated AI platform commercial readiness for its RADR® platform and received FDA regulatory guidance for Starlight Therapeutics' planned pediatric CNS cancer trial.
Nov 13, 2025, 2:00 PM
Lantern Pharma Reports Q3 2025 Results, Advances Clinical Programs, and Commercializes AI Platform
LTRN
Earnings
Product Launch
New Projects/Investments
- Lantern Pharma reported a net loss of $4.2 million, or $0.39 per share, for the third quarter of 2025. As of September 30, 2025, the company had approximately $12.4 million in cash, cash equivalents, and marketable securities, which is expected to provide a cash runway into approximately Q3 2026.
- The LP-184 Phase 1a clinical trial successfully met all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients and validating its AI-driven precision medicine approach. The company plans to advance LP-184 into multiple targeted Phase 1b/Phase 2 trials for four high-value indications with a combined annual market potential exceeding $7 billion.
- Preliminary Phase II data from the LP-300 Harmonic trial showed an 86% clinical benefit rate, with a comprehensive data update planned for December. Additionally, the LP-284 program for non-Hodgkin's lymphoma demonstrated a complete metabolic response in a heavily pretreated patient as monotherapy.
- Lantern Pharma is advancing the commercialization of its RADR AI platform, showcasing modules like PredictBBB (94% accuracy for BBB permeability) and LBX AI (86-90% accuracy for treatment response prediction). The company also introduced Zeta, a new multi-agentic AI platform for rare cancer drug development, with a broader rollout planned for Q1 2026.
Nov 13, 2025, 2:00 PM
Lantern Pharma Reports Q3 2025 Results and Advances Clinical Pipeline and AI Platform
LTRN
Earnings
Guidance Update
New Projects/Investments
- Lantern Pharma reported a net loss of approximately $4.2 million, or $0.39 per share, for the third quarter of 2025.
- The LP-184 Phase I-A clinical trial successfully achieved all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients, validating its AI-driven precision medicine approach. The company plans to advance LP-184 into multiple targeted Phase I-B/II trials for four high-value indications with a combined annual market potential exceeding $7 billion.
- As of September 30, 2025, the company held approximately $12.4 million in cash, cash equivalents, and marketable securities, which is expected to provide a cash runway into approximately Q3 2026. Lantern Pharma anticipates needing substantial additional funding in the near future.
- The company showcased the commercial readiness of its RADR AI platform modules, including PredictBBB with 94% accuracy for BBB permeability prediction, and introduced Zeta, a new multi-agentic AI platform for rare cancers.
Nov 13, 2025, 2:00 PM
Quarterly earnings call transcripts for Lantern Pharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more